Metagenomi Therapeutics (MGX) EBT Margin (2023 - 2026)
Metagenomi Therapeutics (MGX) reported EBT Margin of 1846.88% for Q1 2026, down 124254.0% year-over-year from N/an in Q1 2025, and down 221.11% quarter-over-quarter from 575.15% in Q4 2025.
Metagenomi Therapeutics (MGX) EBT Margin (2023 - 2026) Analysis & Trends
Metagenomi Therapeutics (MGX) has 4 years of EBT Margin data on file, last reported at 1846.88% in Q1 2026.
- EBT Margin for Q1 2026 came in at 1846.88%, down 124254.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 385.27% (down 20109.0% YoY), and the FY2025 annual result was 348.77%, down 18897.0% from the prior year.
- EBT Margin retreated to 1846.88% in Q1 2026 per MGX's latest filing, from 575.15% in the prior quarter.
- Over five years, EBT Margin peaked at 64.66% in Q2 2024 and troughed at 1846.88% in Q1 2026.
- A 4-year average of 366.8% and a median of 225.36% in 2024 frame the typical range for EBT Margin.
- The sharpest annual moves came in 2024 and 2026: EBT Margin surged 3333 bps in 2024, then sank 124254 bps in 2026.
- A 4-year view of EBT Margin shows it stood at 133.62% in 2023, then sank by 92 bps to 255.94% in 2024, then plunged by 125 bps to 575.15% in 2025, then plunged by 221 bps to 1846.88% in 2026.
- Business Quant data shows MGX's EBT Margin at 1846.88% in Q1 2026, 575.15% in Q4 2025, and 238.21% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 821,726.73 Bn | 821,726.69 Bn | - | - |
| 2 | Belite Bio | 57,768.00 Bn | 57,768.00 Bn | - | - |
| 3 | Quantum Biopharma | 16,655.88 Bn | 16,655.88 Bn | - | - |
| 4 | Legend Biotech | 3,540.00 Bn | 3,539.71 Bn | 242.10 Mn | 6.40% |
| 5 | Evaxion A | 1,526.26 Bn | 1,526.24 Bn | - | - |
| 6 | Akari Therapeutics | 1,520.09 Bn | 1,520.09 Bn | - | - |
| 7 | Psyence Biomedical | 223.87 Bn | 223.87 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.47 Bn | 107.23 Bn | 2.59 Bn | 41.95% |
| 9 | Abivax | 91.22 Bn | 91.22 Bn | - | - |
| 10 | Metagenomi Therapeutics | 42.84 Mn | 42.84 Mn | - | -1,846.88% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,846.88% |
| Dec 31, 2025 | -575.15% |
| Sep 30, 2025 | -238.21% |
| Jun 30, 2025 | -233.34% |
| Mar 31, 2025 | -604.34% |
| Dec 31, 2024 | -255.94% |
| Sep 30, 2024 | -181.34% |
| Jun 30, 2024 | -64.66% |
| Mar 31, 2024 | -225.36% |
| Dec 31, 2023 | -133.62% |
| Sep 30, 2023 | -150.56% |
| Jun 30, 2023 | -98.00% |
| Mar 31, 2023 | -160.98% |